- Home
- GNLN vs KZIA Comparison
GNLN vs KZIA Comparison
Compare GNLN & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNLN
- KZIA
- Stock Information
- Founded
- GNLN 2005
- KZIA 1994
- Country
- GNLN United States
- KZIA Australia
- Employees
- GNLN N/A
- KZIA N/A
- Industry
- GNLN Durable Goods
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- GNLN Consumer Discretionary
- KZIA Health Care
- Exchange
- GNLN Nasdaq
- KZIA Nasdaq
- Market Cap
- GNLN 5.8M
- KZIA 5.1M
- IPO Year
- GNLN 2019
- KZIA 1999
- Fundamental
- Price
- GNLN $0.01
- KZIA $5.65
- Analyst Decision
- GNLN
- KZIA Strong Buy
- Analyst Count
- GNLN 0
- KZIA 2
- Target Price
- GNLN N/A
- KZIA $57.50
- AVG Volume (30 Days)
- GNLN 290.1M
- KZIA 24.0K
- Earning Date
- GNLN 05-15-2025
- KZIA 06-17-2025
- Dividend Yield
- GNLN N/A
- KZIA N/A
- EPS Growth
- GNLN N/A
- KZIA N/A
- EPS
- GNLN N/A
- KZIA N/A
- Revenue
- GNLN $9,818,000.00
- KZIA $1,655,324.00
- Revenue This Year
- GNLN $1,541.21
- KZIA N/A
- Revenue Next Year
- GNLN N/A
- KZIA N/A
- P/E Ratio
- GNLN N/A
- KZIA N/A
- Revenue Growth
- GNLN N/A
- KZIA 248000.00
- 52 Week Low
- GNLN $0.01
- KZIA $2.86
- 52 Week High
- GNLN $21.80
- KZIA $79.00
- Technical
- Relative Strength Index (RSI)
- GNLN 20.26
- KZIA 78.10
- Support Level
- GNLN $0.01
- KZIA $3.54
- Resistance Level
- GNLN $0.01
- KZIA $4.00
- Average True Range (ATR)
- GNLN 0.00
- KZIA 0.50
- MACD
- GNLN 0.01
- KZIA 0.25
- Stochastic Oscillator
- GNLN 20.00
- KZIA 86.07
About GNLN Greenlane Holdings Inc.
Greenlane Holdings Inc is a platform for the development and distribution of premium cannabis accessories, vape devices, and lifestyle products. It provides a wide array of consumer ancillary products and industrial ancillary products to thousands of cannabis producers, processors, brands, and retailers (Cannabis Operators). In addition, it serves specialty retailers, smoke shops, head shops, convenience stores, and consumers directly through its proprietary web stores and large online marketplaces such as Amazon. Its geographical segment includes the United States, Canada, and Europe. It derives a majority of revenue from the United States.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.